We extracted data on TnI and NT-proBNP levels (mean, SD and sample size) simultaneously before and after treatment from the four studies that reported data on MPO levels for further meta-analysis to assess the value of early MPO levels as an indicator of cancer-therapy-related cardiotoxicity and to assess the heterogeneity of the studies [16,19]. The gene discussed is NPPB; the disease is cancer.